Enamel Matrix Derivative and Systemic Antibiotics as Adjuncts to Non‐Surgical Periodontal Treatment: Biologic Response

• Published in: Journal of periodontology (1970) 2006-04, Vol.77 (4), p.707-713
• Main Authors: Giannopoulou, C., Andersen, E., Brochut, P., Plagnat, D., Mombelli, A.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Amoxicillin - therapeutic use; Anti-Infective Agents - therapeutic use; Antibiotics; Dental Enamel Proteins - therapeutic use; Dental Scaling; Dentistry; enamel matrix protein; Female; gingival crevicular fluid; Gingival Crevicular Fluid - chemistry; Humans; Inflammation Mediators - analysis; Inflammation Mediators - metabolism; Interleukin-1 - analysis; Interleukin-1 - biosynthesis; Leukocyte L1 Antigen Complex - analysis; Leukocyte L1 Antigen Complex - biosynthesis; Linear Models; Male; Metronidazole - therapeutic use; Middle Aged; Pancreatic Elastase - analysis; Pancreatic Elastase - biosynthesis; Periodontitis - drug therapy; Periodontitis - metabolism; Prospective Studies; Statistics, Nonparametric; treatment
• ISSN: 0022-3492; 1943-3670
• DOI: 10.1902/jop.2006.050166

Background: Short‐term clinical observations suggest an anti‐inflammatory effect of enamel matrix derivative (EMD). The purpose of this study was to evaluate the anti‐inflammatory capacity of EMD, used as an adjunct to non‐surgical periodontal treatment of deep lesions in chronic periodontitis patients, by monitoring inflammatory markers in gingival crevicular fluid (GCF). Methods: Sixteen subjects were randomly assigned to treatment with EMD or placebo in contralateral dentition areas. Half of the subjects received 250 mg metronidazole and 375 mg amoxicillin three times a day for 7 days; the other half received a placebo. GCF samples were collected from one interproximal lesion in each of the contralateral quadrants before treatment and after 10 days and 2, 6, and 12 months. Total protein content was determined according to the Bradford method. Myeloid‐related protein (MRP) 8/14 and interleukin (IL)‐1β were analyzed quantitatively by enzyme‐linked immunosorbent assay (ELISA), and elastase activity was determined using a low molecular weight fluorogenic substrate. Results: No significant differences were observed between sites treated with or without EMD for any biochemical parameter. Two months after treatment, subjects treated with antibiotics exhibited less clinical signs of inflammation. Furthermore, these subjects had lower MRP 8/14 levels only at day 10 compared to those receiving the placebo. For total protein, IL‐1β, and elastase, no statistically significant differences were noted for subjects with or without antibiotic therapy at any time point. Conclusions: Improved healing of the soft tissues has been noted clinically in non‐surgically treated sites in subjects treated with antibiotics. The expression of inflammatory mediators in GCF corroborated this finding only in part. EMD did not seem to further affect the expression of inflammatory mediators.